Fingernails in Evaluating Bone Health in Postmenopausal Women With Breast Cancer Undergoing Hormone Therapy on Clinical Trial IBCSG-1-98
July 26, 2012 updated by: ETOP IBCSG Partners Foundation
Investigating the Chemical Properties of Fingernails to Determine the Efficacy of Nail Structure for Evaluating Bone Fragility
RATIONALE: Studying samples of fingernails in the laboratory from patients with breast cancer may help in evaluating bone health in postmenopausal women undergoing hormone therapy for breast cancer.
PURPOSE: This laboratory study is examining fingernails as a way of evaluating bone health in postmenopausal women with breast cancer undergoing hormone therapy on clinical trial IBCSG-1-98.
Study Overview
Status
Terminated
Conditions
Intervention / Treatment
Detailed Description
OBJECTIVES:
Primary
- Compare the effects of tamoxifen vs letrozole on the chemical properties of fingernails by Raman spectroscopy in postmenopausal women with breast cancer undergoing adjuvant hormonal therapy on protocol IBCSG-1-98.
- Determine the efficacy of nail structure for evaluating bone fragility.
Secondary
- Compare fingernail assessments in patients who have had a bone fracture vs those who have not.
- Determine the natural variation in chemical (Raman spectroscopy) properties of 2 fingernails sourced at 1 appointment from the same donor.
- Evaluate the effect of further drug treatment (after 6 months) on the chemical properties of fingernails.
OUTLINE: This is a single-blind, multicenter, pilot study. Patients are stratified according to treatment on protocol IBCSG-1-98 (tamoxifen vs letrozole) and bone fracture (yes vs no).
Fingernail clippings are collected at baseline and 6 months later. Fingernail clippings are examined by Raman spectroscopy.
PROJECTED ACCRUAL: A total of 60 patients will be accrued for this study.
Study Type
Interventional
Enrollment (Anticipated)
60
Phase
- Phase 3
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
30 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
Female
Description
DISEASE CHARACTERISTICS:
Enrolled on protocol IBCSG-1-98
- Currently receiving (i.e., have not yet completed) 5 years of treatment with tamoxifen or letrozole and expected to receive ≥ 6 months of additional treatment on protocol IBCSG-1-98
- No recurrent breast cancer or second primary cancer
- No known bone disease (including osteomalacia or osteogenesis imperfecta)
Hormone receptor status
- Estrogen and/or progesterone receptor positive tumor
PATIENT CHARACTERISTICS:
- Female
- Postmenopausal
- No uncontrolled thyroid or parathyroid disease, Cushing's disease, or other pituitary diseases
- No malabsorption syndrome or clinically relevant vitamin D deficiency
PRIOR CONCURRENT THERAPY:
- See Disease Characteristics
- More than 1 year since prior and no concurrent anticonvulsants
- More than 6 months since prior and no concurrent corticosteroids at doses > the equivalent of 5 mg/day of prednisone for > 2 weeks total
- No prior or concurrent sodium fluoride at daily doses ≥ 5 mg/day for > 1 month
- More than 12 months since prior and no concurrent anabolic steroids
- More than 6 months since any prior drug for the prevention of osteoporosis (excluding calcium or cholecalciferol [vitamin D])
- Concurrent warfarin allowed provided duration of treatment is no more than 4 weeks
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Triple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: tamoxifen and no bone fracture
Patients randomized to Arm A of Study BIG 1-98 (tamoxifen for 5 years) who have not had a bone fracture.
|
Nails will be chemically characterized using Raman spectroscopy.
|
|
Experimental: Letrozole and no bone fracture
Patients randomized to Arm B of Study BIG 1-98 (letrozole for 5 years) who have not had a bone fracture.
|
Nails will be chemically characterized using Raman spectroscopy.
|
|
Experimental: Tamoxifen and bone fracture
Patients randomized to Arm A of Study BIG 1-98 (tamoxifen for 5 years) who have had a bone fracture.
|
Nails will be chemically characterized using Raman spectroscopy.
|
|
Experimental: Letrozole and bone fracture
Patients randomized to Arm B of Study BIG 1-98 (letrozole for 5 years) who have had a bone fracture.
|
Nails will be chemically characterized using Raman spectroscopy.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Determination of bone health using fingernail assessments at baseline and 6 months
Time Frame: At baseline and 6 months after inclusion in the trial
|
At baseline and 6 months after inclusion in the trial
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Study Chair: Mark Towler, MD, Materials & Surface Science Institute at the University of Limerick
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
April 1, 2005
Primary Completion (Actual)
July 1, 2007
Study Completion (Actual)
July 1, 2007
Study Registration Dates
First Submitted
May 9, 2009
First Submitted That Met QC Criteria
May 9, 2009
First Posted (Estimate)
May 12, 2009
Study Record Updates
Last Update Posted (Estimate)
July 27, 2012
Last Update Submitted That Met QC Criteria
July 26, 2012
Last Verified
July 1, 2012
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- CDR0000482403
- IBCSG-18-98-FPS (Other Identifier: International Breast Cancer Study Group)
- IBCSG-1-98-FPS (Other Identifier: International Breast Cancer Study Group)
- EU-20625
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.